{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,30]],"date-time":"2026-04-30T16:33:27Z","timestamp":1777566807807,"version":"3.51.4"},"reference-count":55,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2022,1,24]],"date-time":"2022-01-24T00:00:00Z","timestamp":1642982400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2022,1,24]],"date-time":"2022-01-24T00:00:00Z","timestamp":1642982400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Transl Med"],"published-print":{"date-parts":[[2022,12]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Background<\/jats:title>\n                <jats:p>The chemokine receptor CCR5 is the major coreceptor for HIV-1 cell entry. We previously observed that not all CCR5 mAbs reduce HIV-1 infection, suggesting that only some CCR5 populations are permissive for HIV-1 entry. This study aims to better understand the relevant conformational states of the cellular coreceptor, CCR5, involved in HIV entry. We hypothesized that CCR5 assumes multiple configurations during normal cycling on the plasma membrane, but only particular forms facilitate HIV-1 infection.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Methods<\/jats:title>\n                <jats:p>To this end, we quantified different CCR5 populations using six CCR5 monoclonal antibodies (mAbs) with different epitope specificities and visualized them with super-resolution microscopy. We quantified each surface CCR5 population before and after HIV-1 infection.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Results<\/jats:title>\n                <jats:p>Based on CCR5 conformational changes, down-modulation, and trafficking rates (internalization and recycling kinetics), we were able to distinguish among heterogeneous CCR5 populations and thus which populations might best be targeted to inhibit HIV-1 entry. We assume that a decreased surface presence of a particular CCR5 subpopulation following infection means that it has been internalized due to HIV-1 entry, and that it therefore represents a highly relevant target for future antiviral therapy strategies. Strikingly, this was most true for antibody CTC8, which targets the N-terminal region of CCR5 and blocks viral entry more efficiently than it blocks chemokine binding.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusions<\/jats:title>\n                <jats:p>Defining the virus-host interactions responsible for HIV-1 transmission, including specific coreceptor populations capable of establishing de novo infections, is essential for the development of an HIV-1 vaccine. This study hopefully will facilitate further development of inhibitors to block CCR5 usage by HIV-1, as well as inform future HIV-1 vaccine design.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1186\/s12967-022-03243-8","type":"journal-article","created":{"date-parts":[[2022,1,24]],"date-time":"2022-01-24T13:10:05Z","timestamp":1643029805000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":13,"title":["Identifying CCR5 coreceptor populations permissive for HIV-1 entry and productive infection: implications for in vivo studies"],"prefix":"10.1186","volume":"20","author":[{"given":"Matthew","family":"Weichseldorfer","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yutaka","family":"Tagaya","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marvin","family":"Reitz","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Anthony L.","family":"DeVico","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Olga S.","family":"Latinovic","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2022,1,24]]},"reference":[{"issue":"9","key":"3243_CR1","doi-asserted-by":"crossref","first-page":"1232","DOI":"10.1097\/QAD.0b013e3283471edb","volume":"25","author":"O Latinovic","year":"2011","unstructured":"Latinovic O, et al. Synergistic inhibition of R5 HIV-1 by maraviroc and CCR5 antibody HGS004 in primary cells: implications for treatment and prevention. AIDS. 2011;25(9):1232\u20135.","journal-title":"AIDS"},{"key":"3243_CR2","first-page":"1497","volume":"1","author":"O Latinovic","year":"2009","unstructured":"Latinovic O, et al. Pharmacotherapy of HIV-1 infection: focus on CCR5 antagonist maraviroc. Clin Med Ther. 2009;1:1497\u2013510.","journal-title":"Clin Med Ther"},{"issue":"51","key":"3243_CR3","doi-asserted-by":"crossref","first-page":"20476","DOI":"10.1073\/pnas.0810843106","volume":"105","author":"A Heredia","year":"2008","unstructured":"Heredia A, et al. Reduction of CCR5 with low-dose rapamycin enhances the antiviral activity of vicriviroc against both sensitive and drug-resistant HIV-1. Proc Natl Acad Sci USA. 2008;105(51):20476\u201381.","journal-title":"Proc Natl Acad Sci USA"},{"issue":"21","key":"3243_CR4","doi-asserted-by":"crossref","first-page":"2677","DOI":"10.1101\/gad.833300","volume":"14","author":"RW Doms","year":"2000","unstructured":"Doms RW, Trono D. The plasma membrane as a combat zone in the HIV battlefield. Genes Dev. 2000;14(21):2677\u201388.","journal-title":"Genes Dev"},{"issue":"14","key":"3243_CR5","doi-asserted-by":"crossref","first-page":"9617","DOI":"10.1074\/jbc.274.14.9617","volume":"274","author":"B Lee","year":"1999","unstructured":"Lee B, et al. Epitope mapping of CCR5 reveals multiple conformational states and distinct but overlapping structures involved in chemokine and coreceptor function. J Biol Chem. 1999;274(14):9617\u201326.","journal-title":"J Biol Chem"},{"issue":"8","key":"3243_CR6","doi-asserted-by":"crossref","first-page":"1373","DOI":"10.1084\/jem.186.8.1373","volume":"186","author":"L Wu","year":"1997","unstructured":"Wu L, et al. Interaction of chemokine receptor CCR5 with its ligands: multiple domains for HIV-1 gp120 binding and a single domain for chemokine binding. J Exp Med. 1997;186(8):1373\u201381.","journal-title":"J Exp Med"},{"issue":"7","key":"3243_CR7","doi-asserted-by":"crossref","first-page":"1395","DOI":"10.3390\/v13071395","volume":"13","author":"C Jacquemard","year":"2021","unstructured":"Jacquemard C, et al. Modeling of CCR5 recognition by HIV-1 gp120: how the viral protein exploits the conformational plasticity of the coreceptor. Viruses. 2021;13(7):1395.","journal-title":"Viruses"},{"issue":"11","key":"3243_CR8","doi-asserted-by":"crossref","first-page":"1259","DOI":"10.1038\/nm1197-1259","volume":"3","author":"G Scarlatti","year":"1997","unstructured":"Scarlatti G, et al. In vivo evolution of HIV-1 co-receptor usage and sensitivity to chemokine-mediated suppression. Nat Med. 1997;3(11):1259\u201365.","journal-title":"Nat Med"},{"issue":"13","key":"3243_CR9","doi-asserted-by":"crossref","first-page":"F137","DOI":"10.1097\/00002030-199813000-00001","volume":"12","author":"L Xiao","year":"1998","unstructured":"Xiao L, et al. Adaptation to promiscuous usage of CC and CXC-chemokine coreceptors in vivo correlates with HIV-1 disease progression. AIDS. 1998;12(13):F137\u201343.","journal-title":"AIDS"},{"issue":"3","key":"3243_CR10","doi-asserted-by":"crossref","first-page":"246","DOI":"10.1111\/j.1365-2567.2011.03485.x","volume":"134","author":"LD Bennett","year":"2011","unstructured":"Bennett LD, Fox JM, Signoret N. Mechanisms regulating chemokine receptor activity. Immunology. 2011;134(3):246\u201356.","journal-title":"Immunology"},{"issue":"12","key":"3243_CR11","doi-asserted-by":"crossref","first-page":"6569","DOI":"10.1128\/JVI.00099-13","volume":"87","author":"R Berro","year":"2013","unstructured":"Berro R, et al. Use of G-protein-coupled and -uncoupled CCR5 receptors by CCR5 inhibitor-resistant and -sensitive human immunodeficiency virus type 1 variants. J Virol. 2013;87(12):6569\u201381.","journal-title":"J Virol"},{"issue":"2","key":"3243_CR12","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0089056","volume":"9","author":"AJ Flegler","year":"2014","unstructured":"Flegler AJ, Cianci GC, Hope TJ. CCR5 conformations are dynamic and modulated by localization, trafficking and G protein association. PLoS ONE. 2014;9(2): e89056.","journal-title":"PLoS ONE"},{"key":"3243_CR13","doi-asserted-by":"publisher","DOI":"10.1126\/scisignal.aal2869","author":"J Jin","year":"2018","unstructured":"Jin J, et al. CCR5 adopts three homodimeric conformations that control cell surface delivery. Sci Signal. 2018. https:\/\/doi.org\/10.1126\/scisignal.aal2869.","journal-title":"Sci Signal"},{"issue":"8","key":"3243_CR14","doi-asserted-by":"crossref","first-page":"718","DOI":"10.1089\/aid.2018.0305","volume":"35","author":"OS Latinovic","year":"2019","unstructured":"Latinovic OS, et al. Suppression of active HIV-1 infection in CD34(+) hematopoietic humanized NSG mice by a combination of combined antiretroviral therapy and CCR5 targeting drugs. AIDS Res Hum Retrovir. 2019;35(8):718\u201328.","journal-title":"AIDS Res Hum Retrovir"},{"issue":"11","key":"3243_CR15","doi-asserted-by":"crossref","first-page":"4721","DOI":"10.1128\/AAC.49.11.4721-4732.2005","volume":"49","author":"P Dorr","year":"2005","unstructured":"Dorr P, et al. Maraviroc (UK-427,857), a potent, orally bioavailable, and selective small-molecule inhibitor of chemokine receptor CCR5 with broad-spectrum anti-human immunodeficiency virus type 1 activity. Antimicrob Agents Chemother. 2005;49(11):4721\u201332.","journal-title":"Antimicrob Agents Chemother"},{"issue":"23","key":"3243_CR16","doi-asserted-by":"crossref","first-page":"4635","DOI":"10.1182\/blood-2012-06-436345","volume":"121","author":"PW Hunt","year":"2013","unstructured":"Hunt PW, et al. The immunologic effects of maraviroc intensification in treated HIV-infected individuals with incomplete CD4+ T-cell recovery: a randomized trial. Blood. 2013;121(23):4635\u201346.","journal-title":"Blood"},{"issue":"2","key":"3243_CR17","doi-asserted-by":"crossref","first-page":"178","DOI":"10.1089\/aid.2015.0020","volume":"32","author":"OS Latinovic","year":"2016","unstructured":"Latinovic OS, et al. Full length single chain Fc protein (FLSC IgG1) as a potent antiviral therapy candidate: implications for in vivo studies. AIDS Res Hum Retrovir. 2016;32(2):178\u201386.","journal-title":"AIDS Res Hum Retrovir"},{"issue":"1","key":"3243_CR18","doi-asserted-by":"crossref","first-page":"24","DOI":"10.2174\/1570162X13666150909145150","volume":"14","author":"OS Latinovic","year":"2016","unstructured":"Latinovic OS, et al. Synergistic inhibition of R5 HIV-1 by the fusion protein (FLSC) IgG1 Fc and maraviroc in primary cells: implications for prevention and treatment. Curr HIV Res. 2016;14(1):24\u201336.","journal-title":"Curr HIV Res"},{"issue":"3","key":"3243_CR19","doi-asserted-by":"crossref","first-page":"143","DOI":"10.2165\/11631400-000000000-00000","volume":"26","author":"R Gong","year":"2012","unstructured":"Gong R, Chen W, Dimitrov DS. Candidate antibody-based therapeutics against HIV-1. BioDrugs. 2012;26(3):143\u201362.","journal-title":"BioDrugs"},{"issue":"2","key":"3243_CR20","doi-asserted-by":"crossref","first-page":"104","DOI":"10.1097\/COH.0b013e3283224015","volume":"4","author":"WC Olson","year":"2009","unstructured":"Olson WC, Jacobson JM. CCR5 monoclonal antibodies for HIV-1 therapy. Curr Opin HIV AIDS. 2009;4(2):104\u201311.","journal-title":"Curr Opin HIV AIDS"},{"issue":"2","key":"3243_CR21","doi-asserted-by":"crossref","first-page":"574","DOI":"10.3390\/v2020574","volume":"2","author":"L Lopalco","year":"2010","unstructured":"Lopalco L. CCR5: from natural resistance to a new anti-HIV strategy. Viruses. 2010;2(2):574\u2013600.","journal-title":"Viruses"},{"issue":"1","key":"3243_CR22","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1186\/s12977-016-0326-1","volume":"14","author":"M Gonzalez","year":"2017","unstructured":"Gonzalez M, DeVico AL, Spouge JL. Conserved signatures indicate HIV-1 transmission is under strong selection and thus is not a \u201cstochastic\u201d process. Retrovirology. 2017;14(1):13.","journal-title":"Retrovirology"},{"issue":"3","key":"3243_CR23","doi-asserted-by":"crossref","first-page":"367","DOI":"10.1016\/S0092-8674(00)80110-5","volume":"86","author":"R Liu","year":"1996","unstructured":"Liu R, et al. Homozygous defect in HIV-1 coreceptor accounts for resistance of some multiply-exposed individuals to HIV-1 infection. Cell. 1996;86(3):367\u201377.","journal-title":"Cell"},{"issue":"10","key":"3243_CR24","doi-asserted-by":"crossref","first-page":"F67","DOI":"10.1097\/00002030-199710000-00001","volume":"11","author":"C Balotta","year":"1997","unstructured":"Balotta C, et al. Homozygous delta 32 deletion of the CCR-5 chemokine receptor gene in an HIV-1-infected patient. AIDS. 1997;11(10):F67-71.","journal-title":"AIDS"},{"issue":"1","key":"3243_CR25","doi-asserted-by":"crossref","first-page":"54","DOI":"10.3390\/v6010054","volume":"6","author":"BP Burke","year":"2013","unstructured":"Burke BP, et al. CCR5 as a natural and modulated target for inhibition of HIV. Viruses. 2013;6(1):54\u201368.","journal-title":"Viruses"},{"issue":"11","key":"3243_CR26","doi-asserted-by":"crossref","first-page":"F73","DOI":"10.1097\/00002030-199711000-00001","volume":"11","author":"L Meyer","year":"1997","unstructured":"Meyer L, et al. Early protective effect of CCR-5 delta 32 heterozygosity on HIV-1 disease progression: relationship with viral load. The SEROCO study group. Aids. 1997;11(11):F73\u20138.","journal-title":"Aids"},{"issue":"15","key":"3243_CR27","doi-asserted-by":"crossref","first-page":"1833","DOI":"10.1097\/00002030-199715000-00007","volume":"11","author":"GJ Stewart","year":"1997","unstructured":"Stewart GJ, et al. Increased frequency of CCR-5 delta 32 heterozygotes among long-term non-progressors with HIV-1 infection. The Australian long-term non-progressor study group. Aids. 1997;11(15):1833\u20138.","journal-title":"Aids"},{"issue":"9","key":"3243_CR28","doi-asserted-by":"crossref","first-page":"782","DOI":"10.7326\/0003-4819-135-9-200111060-00008","volume":"135","author":"JP Ioannidis","year":"2001","unstructured":"Ioannidis JP, et al. Effects of CCR5-Delta32, CCR2-64I, and SDF-1 3\u2019A alleles on HIV-1 disease progression: an international meta-analysis of individual-patient data. Ann Intern Med. 2001;135(9):782\u201395.","journal-title":"Ann Intern Med"},{"key":"3243_CR29","first-page":"339","volume":"8","author":"H Taha","year":"2015","unstructured":"Taha H, Das A, Das S. Clinical effectiveness of dolutegravir in the treatment of HIV\/AIDS. Infect Drug Resist. 2015;8:339\u201352.","journal-title":"Infect Drug Resist"},{"issue":"3","key":"3243_CR30","doi-asserted-by":"crossref","first-page":"857","DOI":"10.1016\/j.idc.2019.04.007","volume":"33","author":"N Jilg","year":"2019","unstructured":"Jilg N, Li JZ. On the road to a HIV cure: moving beyond Berlin and London. Infect Dis Clin N Am. 2019;33(3):857\u201368.","journal-title":"Infect Dis Clin N Am"},{"issue":"24","key":"3243_CR31","doi-asserted-by":"crossref","first-page":"15590","DOI":"10.1073\/pnas.242134499","volume":"99","author":"YL Lin","year":"2002","unstructured":"Lin YL, et al. Cell surface CCR5 density determines the postentry efficiency of R5 HIV-1 infection. Proc Natl Acad Sci USA. 2002;99(24):15590\u20135.","journal-title":"Proc Natl Acad Sci USA"},{"issue":"2","key":"3243_CR32","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1093\/infdis\/jiq023","volume":"203","author":"G Catano","year":"2011","unstructured":"Catano G, et al. Concordance of CCR5 genotypes that influence cell-mediated immunity and HIV-1 disease progression rates. J Infect Dis. 2011;203(2):263\u201372.","journal-title":"J Infect Dis"},{"key":"3243_CR33","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1016\/j.antiviral.2014.10.006","volume":"112","author":"O Latinovic","year":"2014","unstructured":"Latinovic O, et al. Binding of fusion protein FLSC IgG1 to CCR5 is enhanced by CCR5 antagonist maraviroc. Antiviral Res. 2014;112:80\u201390.","journal-title":"Antiviral Res"},{"issue":"14","key":"3243_CR34","doi-asserted-by":"crossref","first-page":"1429","DOI":"10.1056\/NEJMoa0803152","volume":"359","author":"RM Gulick","year":"2008","unstructured":"Gulick RM, et al. Maraviroc for previously treated patients with R5 HIV-1 infection. N Engl J Med. 2008;359(14):1429\u201341.","journal-title":"N Engl J Med"},{"issue":"6","key":"3243_CR35","doi-asserted-by":"crossref","first-page":"477","DOI":"10.1089\/aid.2006.22.477","volume":"22","author":"JR Vu","year":"2006","unstructured":"Vu JR, et al. An immunoglobulin fusion protein based on the gp120-CD4 receptor complex potently inhibits human immunodeficiency virus type 1 in vitro. AIDS Res Hum Retrovir. 2006;22(6):477\u201390.","journal-title":"AIDS Res Hum Retrovir"},{"issue":"7","key":"3243_CR36","doi-asserted-by":"crossref","first-page":"692","DOI":"10.1056\/NEJMoa0802905","volume":"360","author":"G Hutter","year":"2009","unstructured":"Hutter G, et al. Long-term control of HIV by CCR5 Delta32\/Delta32 stem-cell transplantation. N Engl J Med. 2009;360(7):692\u20138.","journal-title":"N Engl J Med"},{"issue":"2","key":"3243_CR37","doi-asserted-by":"crossref","first-page":"178","DOI":"10.1086\/518799","volume":"196","author":"B Clotet","year":"2007","unstructured":"Clotet B. CCR5 inhibitors: promising yet challenging. J Infect Dis. 2007;196(2):178\u201380.","journal-title":"J Infect Dis"},{"issue":"1","key":"3243_CR38","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1189\/jlb.2A0414-193RR","volume":"98","author":"JM Fox","year":"2015","unstructured":"Fox JM, et al. CCR5 susceptibility to ligand-mediated down-modulation differs between human T lymphocytes and myeloid cells. J Leukoc Biol. 2015;98(1):59\u201371.","journal-title":"J Leukoc Biol"},{"issue":"7","key":"3243_CR39","doi-asserted-by":"crossref","first-page":"815","DOI":"10.1001\/jama.296.7.815","volume":"296","author":"MM Lederman","year":"2006","unstructured":"Lederman MM, et al. Biology of CCR5 and its role in HIV infection and treatment. JAMA. 2006;296(7):815\u201326.","journal-title":"JAMA"},{"issue":"19","key":"3243_CR40","doi-asserted-by":"crossref","first-page":"17291","DOI":"10.1074\/jbc.M108232200","volume":"277","author":"SM Brandt","year":"2002","unstructured":"Brandt SM, et al. Association of chemokine-mediated block to HIV entry with coreceptor internalization. J Biol Chem. 2002;277(19):17291\u20139.","journal-title":"J Biol Chem"},{"issue":"1","key":"3243_CR41","doi-asserted-by":"crossref","first-page":"396","DOI":"10.1128\/JVI.72.1.396-404.1998","volume":"72","author":"A Trkola","year":"1998","unstructured":"Trkola A, et al. Genetic subtype-independent inhibition of human immunodeficiency virus type 1 replication by CC and CXC chemokines. J Virol. 1998;72(1):396\u2013404.","journal-title":"J Virol"},{"issue":"23","key":"3243_CR42","doi-asserted-by":"crossref","first-page":"9475","DOI":"10.1073\/pnas.1222205110","volume":"110","author":"P Colin","year":"2013","unstructured":"Colin P, et al. HIV-1 exploits CCR5 conformational heterogeneity to escape inhibition by chemokines. Proc Natl Acad Sci USA. 2013;110(23):9475\u201380.","journal-title":"Proc Natl Acad Sci USA"},{"issue":"12","key":"3243_CR43","doi-asserted-by":"crossref","first-page":"6637","DOI":"10.1128\/JVI.77.12.6637-6644.2003","volume":"77","author":"O Hartley","year":"2003","unstructured":"Hartley O, et al. Human immunodeficiency virus type 1 entry inhibitors selected on living cells from a library of phage chemokines. J Virol. 2003;77(12):6637\u201344.","journal-title":"J Virol"},{"issue":"8","key":"3243_CR44","doi-asserted-by":"crossref","first-page":"1215","DOI":"10.1084\/jem.187.8.1215","volume":"187","author":"M Mack","year":"1998","unstructured":"Mack M, et al. Aminooxypentane-RANTES induces CCR5 internalization but inhibits recycling: a novel inhibitory mechanism of HIV infectivity. J Exp Med. 1998;187(8):1215\u201324.","journal-title":"J Exp Med"},{"issue":"10","key":"3243_CR45","doi-asserted-by":"crossref","DOI":"10.1126\/sciadv.aax0821","volume":"5","author":"G Boncompain","year":"2019","unstructured":"Boncompain G, et al. Targeting CCR5 trafficking to inhibit HIV-1 infection. Sci Adv. 2019;5(10): eaax0821.","journal-title":"Sci Adv"},{"issue":"6","key":"3243_CR46","doi-asserted-by":"crossref","first-page":"3426","DOI":"10.4049\/jimmunol.164.6.3426","volume":"164","author":"L Lopalco","year":"2000","unstructured":"Lopalco L, et al. CCR5-reactive antibodies in seronegative partners of HIV-seropositive individuals down-modulate surface CCR5 in vivo and neutralize the infectivity of R5 strains of HIV-1 in vitro. J Immunol. 2000;164(6):3426\u201333.","journal-title":"J Immunol"},{"issue":"7","key":"3243_CR47","doi-asserted-by":"crossref","first-page":"4347","DOI":"10.1128\/JVI.79.7.4347-4356.2005","volume":"79","author":"EJ Platt","year":"2005","unstructured":"Platt EJ, Durnin JP, Kabat D. Kinetic factors control efficiencies of cell entry, efficacies of entry inhibitors, and mechanisms of adaptation of human immunodeficiency virus. J Virol. 2005;79(7):4347\u201356.","journal-title":"J Virol"},{"issue":"27","key":"3243_CR48","doi-asserted-by":"crossref","first-page":"19042","DOI":"10.1074\/jbc.M114.559831","volume":"289","author":"J Jin","year":"2014","unstructured":"Jin J, et al. Targeting spare CC chemokine receptor 5 (CCR5) as a principle to inhibit HIV-1 entry. J Biol Chem. 2014;289(27):19042\u201352.","journal-title":"J Biol Chem"},{"issue":"10","key":"3243_CR49","doi-asserted-by":"crossref","first-page":"835","DOI":"10.1089\/aid.2020.0064","volume":"36","author":"M Weichseldorfer","year":"2020","unstructured":"Weichseldorfer M, et al. Anti-HIV activity of standard combined antiretroviral therapy in primary cells is intensified by CCR5-targeting drugs. AIDS Res Hum Retrovir. 2020;36(10):835\u201341.","journal-title":"AIDS Res Hum Retrovir"},{"issue":"12","key":"3243_CR50","doi-asserted-by":"crossref","first-page":"i","DOI":"10.1038\/nmeth.f.388","volume":"12","author":"J Huff","year":"2015","unstructured":"Huff J. The Airyscan detector from ZEISS: confocal imaging with improved signal-to-noise ratio and super-resolution. Nat Methods. 2015;12(12):i\u2013ii.","journal-title":"Nat Methods"},{"issue":"13","key":"3243_CR51","doi-asserted-by":"crossref","first-page":"2049","DOI":"10.1007\/s00018-009-0001-y","volume":"66","author":"AS Robertson","year":"2009","unstructured":"Robertson AS, Smythe E, Ayscough KR. Functions of actin in endocytosis. Cell Mol Life Sci. 2009;66(13):2049\u201365.","journal-title":"Cell Mol Life Sci"},{"issue":"16","key":"3243_CR52","doi-asserted-by":"crossref","first-page":"8227","DOI":"10.1128\/JVI.00767-11","volume":"85","author":"R Berro","year":"2011","unstructured":"Berro R, et al. Multiple CCR5 conformations on the cell surface are used differentially by human immunodeficiency viruses resistant or sensitive to CCR5 inhibitors. J Virol. 2011;85(16):8227\u201340.","journal-title":"J Virol"},{"issue":"2","key":"3243_CR53","doi-asserted-by":"crossref","first-page":"723","DOI":"10.1091\/mbc.01-03-0129","volume":"13","author":"C Blanpain","year":"2002","unstructured":"Blanpain C, et al. Multiple active states and oligomerization of CCR5 revealed by functional properties of monoclonal antibodies. Mol Biol Cell. 2002;13(2):723\u201337.","journal-title":"Mol Biol Cell"},{"issue":"2","key":"3243_CR54","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1046\/j.1432-1033.2003.03918.x","volume":"271","author":"A Mueller","year":"2004","unstructured":"Mueller A, Strange PG. Mechanisms of internalization and recycling of the chemokine receptor, CCR5. Eur J Biochem. 2004;271(2):243\u201352.","journal-title":"Eur J Biochem"},{"issue":"7","key":"3243_CR55","doi-asserted-by":"crossref","DOI":"10.1128\/JVI.02118-17","volume":"92","author":"S Satheesan","year":"2018","unstructured":"Satheesan S, et al. HIV replication and latency in a humanized NSG Mouse model during suppressive oral combinational antiretroviral therapy. J Virol. 2018;92(7): e02118-17.","journal-title":"J Virol"}],"container-title":["Journal of Translational Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12967-022-03243-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12967-022-03243-8\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12967-022-03243-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,1,24]],"date-time":"2022-01-24T13:16:36Z","timestamp":1643030196000},"score":1,"resource":{"primary":{"URL":"https:\/\/translational-medicine.biomedcentral.com\/articles\/10.1186\/s12967-022-03243-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,1,24]]},"references-count":55,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2022,12]]}},"alternative-id":["3243"],"URL":"https:\/\/doi.org\/10.1186\/s12967-022-03243-8","relation":{},"ISSN":["1479-5876"],"issn-type":[{"value":"1479-5876","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,1,24]]},"assertion":[{"value":"1 December 2021","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 January 2022","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 January 2022","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare that they have no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"39"}}